Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of Haleon (LON:HLN – Get Rating) in a research report released on Wednesday morning, MarketBeat reports. They currently have a GBX 300 ($3.62) target price on the stock.
Several other research analysts also recently issued reports on HLN. Citigroup restated a buy rating and set a GBX 360 ($4.35) price objective on shares of Haleon in a research report on Thursday, July 21st. Barclays upgraded Haleon to an equal weight rating and set a GBX 348 ($4.20) price target for the company in a report on Tuesday, July 19th. JPMorgan Chase & Co. cut their price target on Haleon from GBX 280 ($3.38) to GBX 250 ($3.02) and set an underweight rating for the company in a report on Wednesday, September 7th. Credit Suisse Group reiterated an outperform rating and issued a GBX 368 ($4.45) price target on shares of Haleon in a report on Tuesday, July 19th. Finally, Royal Bank of Canada reiterated a sector perform rating and issued a GBX 300 ($3.62) price target on shares of Haleon in a report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Haleon has a consensus rating of Hold and a consensus price target of GBX 321 ($3.88).
Haleon Price Performance
Shares of Haleon stock opened at GBX 264.90 ($3.20) on Wednesday. The company has a debt-to-equity ratio of 40.61, a current ratio of 3.04 and a quick ratio of 0.59. Haleon has a 1 year low of GBX 241.17 ($2.91) and a 1 year high of GBX 337.40 ($4.08). The firm has a market cap of £24.46 billion and a P/E ratio of 1,784.00. The stock’s 50 day moving average is GBX 276.35.
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.